Using the blood protein vasorin to distinguish septic shock from other shocks
Official title: Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock
Run by Centre Hospitalier Universitaire, Amiens · NCT07203833 · Data updated 2026-11-12
This project will test whether measuring vasorin in blood can tell adults in the ICU with septic shock apart from those with non-septic shock.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 144 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens) |
| Status | Recruiting |
| Started | October 19, 2025 |
| Main results expected | April 2027 |
| Study ends | May 2027 |
| Registry record updated | January 7, 2026 |
| Trial ID | NCT07203833 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) admitted to the CHU Amiens‑Picardie ICU within 24 hours who require vasopressors for shock with lactate ≥2 mmol/L and meet criteria for either septic (fever and suspected/documented infection) or non‑septic (no fever, no suspected infection) shock.
✕Probably not a fit
Pregnant people, patients admitted more than 24 hours earlier, those without vasopressor‑dependent shock or with lactate <2 mmol/L, and patients treated outside CHU Amiens‑Picardie are not eligible and would not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Septic shock is a life-threatening form of infection for which earlier and more specific biomarkers are needed. The study will enroll adults admitted within 24 hours to the CHU Amiens‑Picardie ICU and collect blood samples to measure plasma vasorin concentrations. Participants are divided into two groups: septic shock (fever with suspected or documented infection, vasopressors and lactate ≥2 mmol/L) and non‑septic shock (no fever or suspected infection, vasopressors and lactate ≥2 mmol/L). Investigators will compare vasorin levels between groups and explore its potential diagnostic and prognostic value compared with existing markers like procalcitonin.
Why it matters
Potential benefit: If successful, vasorin measurement could enable faster, more accurate diagnosis of septic shock and help avoid unnecessary antibiotic treatment.
How similar studies have gone: Preclinical laboratory work links vasorin to septic shock, but clinical application of vasorin as a diagnostic biomarker is novel and not yet proven in larger patient cohorts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults over 18 years. * Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie. * Group 1: patients with septic shock defined by sepsis with 2 mmol/l Lactates, requiring vasopressors to maintain mean blood pressure at 65 mmHg (despite adequate vascular filling) in the presence of fever (T°\>38.3) with a documented or suspected infection * Group 2: patients with a shock defined by arterial hypotension requiring the use of vasopressors with 2 mmol/l Lactates but without suspected infection and apyrexie (T°\<38°). For example: vasoplegia post cardiac surgery with CBP or cardiogenic shock or hemorrhagic shock Exclusion Criteria: * Pregnant women * Group 1 : No evidence of suspected or documented infection * Group 2 : Presence of fever and/or suspected infection
Where it's running
-
CHU Amiens-Picardie
Amiens, France Recruiting
Study contacts
- Study coordinator: Julien Maizel, Pr
- Email: maizel.julien@chu-amiens.fr
- Phone: 33+322087807
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using umbilical mesenchymal stromal cells to treat septic shock
This study is testing whether giving umbilical stem cells can help people with septic shock recover better than a placebo.
-
Adjunctive Fludrocortisone in Septic Shock on Hydrocortisone
In septic shock, this trial tests whether adding fludrocortisone (50 mcg or 100 mcg daily) to hydrocortisone improves survival and recovery compared with placebo.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
-
Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter
This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.
-
Gastric emptying and feeding tolerance in ICU patients by vasopressor dose
This study tests whether vasopressor dose affects how well stomach contents empty during tube feeding in critically ill patients.
-
Personalized Fluid Resuscitation in the Emergency Department
This pilot test checks if a quick, non-invasive stroke-volume assessment can help ED doctors tailor IV fluids for septic patients with low blood pressure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.